Cann Group Stock

Cann Group EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Cann Group (CAN.AX) as of Jul 28, 2026 is -0.89. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.44 — a change of 102.73% (lower).

EV/EBIT

-0.89

YoY

102.73%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Cann Group is 2026 -0.89 . EV/EBIT (Enterprise Value to EBIT) of Cann Group was 2025 -0.44 . It decreases by 102.73% lower compared to the previous year.

The Cann Group EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-26.75 base
Jan 1, 2019
-7.33 base
Jan 1, 2020
-5.43 base
Jan 1, 2021
-3.18 base
Jan 1, 2022
-2.96 base
Jan 1, 2023
-1.25 base
Jan 1, 2024
-0.70 base
Jan 1, 2025
-0.38 base
YEARPRICE-TO-EBIT
2025 -0.38
2024 -0.70
2023 -1.25
2022 -2.96
2021 -3.18
2020 -5.43
2019 -7.33
2018 -26.75
2017 -68.68
2016 -
2015 -
Access this data via the Eulerpool API

Cann Group Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cann Group's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cann Group's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cann Group's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cann Group grows earnings faster than its peers.

Cann Group Stock analysis

What does Cann Group do? Cann Group Ltd is an Australian company specializing in the production and marketing of medical cannabis. The company was founded in 2013 and is headquartered in Melbourne. The company's history began with the founding of an independent consulting firm called AusCann Group Holdings Ltd in 2014. This firm was created to inform Australian and international investors about the opportunities and possibilities in the Australian cannabis market. In 2016, a cooperation agreement was signed between AusCann and Cann Group Ltd to advance the cultivation and production of medical cannabis products in Australia. Since then, Cann Group has continuously invested in the development and growth of the Australian medical cannabis market. The company has obtained a Good Manufacturing Practices (GMP) compliance license to ensure that all products meet the highest quality and safety standards. This includes collaborating with research institutions and state health authorities to investigate the efficacy and safety of medications. Cann Group's various business areas include the production of medical cannabis, research, product development, and marketing. The company operates a cannabis cultivation facility in Cochranes Hill, Victoria, covering an area of 20 hectares. The cultivation of cannabis is carried out under controlled conditions to ensure that all products are of the highest quality and purity. The cultivated cannabis is then used to manufacture medical products such as oils, tinctures, capsules, and sprays. Cann Group also collaborates closely with research institutions and academic institutions to study the safety and efficacy of medical cannabis. The company has partnerships with the University of Melbourne, Queensland University of Technology, and Swinburne University of Technology for research on the mechanisms of cannabis, application research, and studies on the clinical efficacy of cannabis. The business model of Cann Group is based on the sale of medical cannabis products to pharmacies and medical facilities in Australia and worldwide. The company, through its license, is one of the few companies capable of producing and exporting medical cannabis for the Australian market. In addition to exporting cannabis products to Germany, New Zealand, the UK, and other countries, the sale of cannabis products to the Australian market is the largest market for Cann Group. The company offers a variety of medical cannabis products specifically developed for various medical conditions. These include products for anxiety, nausea and vomiting, pain, seizures, and many other diseases. There are also products for palliative care, which help alleviate pain and suffering in the final stages. Overall, Cann Group Ltd has played a pioneering role in the development of the Australian medical cannabis market in recent years. The company specializes in the production of medical cannabis products that meet the highest quality standards and strict regulatory requirements. The company is committed to improving the therapeutic approach to diseases and enhancing the quality of life for patients. Cann Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cann Group stock

EV/EBIT (Enterprise Value to EBIT) of Cann Group is -0.89 in 2026.

Access this data via the Eulerpool API

Valuation — Cann Group

All Key Metrics — Cann Group